Liver Fetuin-A at Initiation of Insulin Resistance.
Kupffer cell
fatty liver
fetuin-A
hepatokine
immunofluorescence
insulin resistance
macrophage
nonalcoholic fatty liver disease
prediabetes
steatosis
Journal
Metabolites
ISSN: 2218-1989
Titre abrégé: Metabolites
Pays: Switzerland
ID NLM: 101578790
Informations de publication
Date de publication:
25 Oct 2022
25 Oct 2022
Historique:
received:
13
09
2022
revised:
18
10
2022
accepted:
22
10
2022
entrez:
10
11
2022
pubmed:
11
11
2022
medline:
11
11
2022
Statut:
epublish
Résumé
Hepatokines (liver secreted proteins with possible distant action) are emerging potential players in insulin resistance in type 2 diabetic patients. Here, we explored the effect of a high-fat diet on the expression of fetuin-A, one of those candidate liver proteins, and its relationship with liver macrophage activation. Mice were fed a normal diet or a high-fat diet for 3 days, known to initiate steatosis and liver insulin resistance. A preventive liver macrophage depletion was obtained by intravenous injection of clodronate-loaded liposomes. The mRNA and protein expression of fetuin-A was evaluated by qPCR, Western blot and immunofluorescence on different insulin-sensitive tissues (liver, adipose tissue, and muscle). Short-term high-fat diet-induced steatosis, liver macrophage activation, and hepatic insulin resistance together with a significantly increased expression of liver AHSG (α2-HS glycoprotein/fetuin-A) mRNA and serum fetuin-A concentration. On immunofluorescence, fetuin-A was mostly expressed in centrilobular hepatocytes. This increase in fetuin-A under high-fat diet was not evidenced in other peripheral insulin-sensitive tissues (skeletal muscle and adipose tissue). The mRNA expression of α2-HS glycoprotein was 800 times higher within the liver compared with the adipose tissue or the muscle. Liver macrophage depletion that significantly ameliorated insulin sensitivity was associated with a significant decrease in α2-HS glycoprotein mRNA expression. In conclusion, this study demonstrated liver fetuin-A overexpression at the initiation of high-fat diet feeding, concurrent with hepatic steatosis and insulin resistance. Targeting liver macrophages in this setting reduced liver α2-HS glycoprotein expression suggesting that fetuin-A acts as an hepatokine with proinsulin resistance effects.
Identifiants
pubmed: 36355106
pii: metabo12111023
doi: 10.3390/metabo12111023
pmc: PMC9693222
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : UCLouvain
ID : Starting grant
Organisme : Fund for Scientific Research
ID : FRS-FNRS Belgium
Références
Clin Sci (Lond). 2013 Dec;125(11):501-11
pubmed: 23758436
Arterioscler Thromb Vasc Biol. 2008 Jan;28(1):27-38
pubmed: 17690317
Medicine (Baltimore). 2015 Sep;94(39):e1517
pubmed: 26426614
World J Gastroenterol. 2020 Apr 28;26(16):1861-1878
pubmed: 32390698
Biomedicines. 2021 Dec 14;9(12):
pubmed: 34944728
Proc Natl Acad Sci U S A. 1981 Aug;78(8):4970-4
pubmed: 7029527
BMJ Open. 2021 Aug 25;11(8):e045498
pubmed: 34433590
Diabetes Care. 2006 Feb;29(2):468
pubmed: 16443916
PLoS One. 2011 Apr 27;6(4):e19228
pubmed: 21556362
Lancet Gastroenterol Hepatol. 2022 May;7(5):388-390
pubmed: 35248211
Acta Gastroenterol Belg. 2022 Apr-Jun;85(2):346-357
pubmed: 35709779
Endocr Rev. 2019 Oct 1;40(5):1367-1393
pubmed: 31098621
Lab Invest. 2007 Jan;87(1):56-65
pubmed: 17075577
Diabetes Care. 2006 Apr;29(4):853-7
pubmed: 16567827
World J Hepatol. 2020 Dec 27;12(12):1168-1181
pubmed: 33442446
Nat Med. 2005 Feb;11(2):183-90
pubmed: 15685173
JHEP Rep. 2019 Feb 23;1(1):30-43
pubmed: 32149275
Metabolites. 2022 Jul 07;12(7):
pubmed: 35888749
Diabetes. 2010 Feb;59(2):347-57
pubmed: 19934001
Acta Gastroenterol Belg. 2018 Jan-Mar;81(1):55-81
pubmed: 29562379
J Nutr. 2020 May 1;150(5):1076-1085
pubmed: 31919514
Gastroenterology. 2020 May;158(7):1999-2014.e1
pubmed: 32044314
Hepatology. 2014 Sep;60(3):1113-4
pubmed: 24452327
Nat Med. 2012 Aug;18(8):1279-85
pubmed: 22842477
J Clin Invest. 2000 Apr;105(8):1067-75
pubmed: 10772651
Proc Natl Acad Sci U S A. 2006 Nov 28;103(48):18273-7
pubmed: 17114290
Hepatology. 2010 Feb;51(2):721-2; author reply 722
pubmed: 20101758
J Clin Endocrinol Metab. 2002 Jul;87(7):3023-8
pubmed: 12107194
Lipids Health Dis. 2018 Dec 22;17(1):291
pubmed: 30579336
FASEB J. 2011 Dec;25(12):4301-11
pubmed: 21873555
Hepatology. 2014 Apr;59(4):1393-405
pubmed: 24254368
Cells. 2022 Aug 31;11(17):
pubmed: 36078124
J Nutr. 2021 Jun 1;151(6):1507-1516
pubmed: 33693866
Acta Gastroenterol Belg. 2020 Oct-Dec;83(4):513-515
pubmed: 33321005
Biochem Biophys Res Commun. 2006 Nov 17;350(2):437-43
pubmed: 17011519
Diabetes. 2002 Aug;51(8):2450-8
pubmed: 12145157
Clin Sci (Lond). 2013 Oct;125(8):391-400
pubmed: 23627434
Metabolism. 2011 Feb;60(2):265-71
pubmed: 20199782
Diabetes. 2013 Jan;62(1):49-55
pubmed: 22923470
J Clin Endocrinol Metab. 2008 Jul;93(7):2702-8
pubmed: 18430773
Diabetes. 2005 Mar;54(3):603-8
pubmed: 15734833
Best Pract Res Clin Gastroenterol. 2014 Aug;28(4):545-58
pubmed: 25194174
Clin Sci (Lond). 2020 Aug 28;134(16):2117-2135
pubmed: 32820802
J Endocrinol Invest. 2021 Jan;44(1):105-110
pubmed: 32350824
World J Hepatol. 2015 Sep 8;7(19):2184-8
pubmed: 26380042
Cell Metab. 2010 Nov 3;12(5):483-95
pubmed: 21035759
Nat Rev Endocrinol. 2017 Sep;13(9):509-520
pubmed: 28621339
Lancet Diabetes Endocrinol. 2022 Apr;10(4):284-296
pubmed: 35183303
Am J Physiol Gastrointest Liver Physiol. 2010 Jan;298(1):G107-16
pubmed: 19875703
J Physiol. 2009 May 15;587(Pt 10):2387-97
pubmed: 19332493
J Biol Chem. 2004 Jul 30;279(31):32345-53
pubmed: 15166226
Metabolites. 2021 Mar 08;11(3):
pubmed: 33800465